ICICI Securities Ltd | Retail Equity Research Biocon's Q3FY19 numbers were a comprehensive beat vis--vis Idirect estimates on all fronts. Revenues grew 45.6% YoY to | 1540.8 crore (I-direct estimate: | 1382.4 crore) mainly due to 136.6% YoY growth in biologics to | 449 crore (I-direct estimate: | 379.6 crore) EBITDA margins improved 375 bps YoY to 24.7% (I-direct estimate: 26.2%) mainly due to improvement in product mix. EBITDA grew 71.7% YoY to | 380.7 crore against I-direct estimates of | 362.1 crore Adjusted net profit grew 131.6% to | 212.9 crore (I-direct estimate:...